Copy Link Print Information

Raltegravir potassium

(Synonyms: MK 0518 potassium)
28 Cited Publications
Avis client

Based on 28 publication(s) in Google Scholar

Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.82%
  • CAS No.: 871038-72-1
  • Formule: C20H20FKN6O5
  • Masse moléculaire:482.51
  • Stockage:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Raltegravir potassium Chemical Structure
    Raltegravir potassium Chemical Structure
  • Experimental Validation Results for Raltegravir potassium
  • Experimental Validation Results for Raltegravir potassium
  • Experimental Validation Results for Raltegravir potassium
  • Experimental Validation Results for Raltegravir potassium
  • Experimental Validation Results for Raltegravir potassium
  • Experimental Validation Results for Raltegravir potassium
  • Experimental Validation Results for Raltegravir potassium
  • Experimental Validation Results for Raltegravir potassium
  • Experimental Validation Results for Raltegravir potassium
CAS No.: 871038-72-1
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Raltegravir potassium:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Protocole
  • Pureté et documentation
  • Références
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Raltegravir potassium

More
Customer Validation & Images
Cell Proliferation/Viability AssayBio/Physico-chemical AssayRT-PCRELISAWB
  • RT-PCR
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • ELISA
  • Bio/Physico-chemical Assay
  • WB
  • WB

Voir tous les produits spécifiques à Isoform HIV

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Raltegravir potassium Chemical Structure
    Raltegravir potassium Chemical Structure
    1/16
  • 1/16

    Raltegravir potassium purchased from MedChemExpress. Usage Cited in: Mol Divers. 2025 Nov 12. [Abstract]

    Customer Validation
     Raltegravir (anti-HIV-1 inhibitor). Integrated HIV-1 provirus DNA was determined by Alu-PCR. Results were normalized with that of the control group and are presented as fold reduction.

  • 1/16

    Raltegravir potassium purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2023 Aug 8;16(8):1118. [Abstract]

    Customer Validation
     Normalized antiviral activity of Raltegravir (48 h) as determined against NL4-3 HIV-1 wild-type strain in TZM-bl cell line. The nonlinear fitting curve as calculated by GraphPad Prism is depicted in red; the black lines indicate the dose-response curves. The R2 of nonlinear fitting curve is 0.913 for Raltegravir.

  • 1/16

    Raltegravir potassium purchased from MedChemExpress. Usage Cited in: Virol Sin. 2023 Jun;38(3):448-458. [Abstract]

    Customer Validation
     VSV-G-pseudotyped HIV-1 virions were added and the inoculated cells were incubated for 24 ​h. Heat inactivated virus (H.I.) and integrase inhibitor Raltegravir (RAL, 30 ​nmol/L) were used as negative controls. After 24 ​h, the total cellular DNA was isolated from virus-infected cells. Integrated HIV-1 DNA was quantified by nested Alu-PCR. The numbers of infected cells and integrated HIV-1 DNA in siRNA-transfected cells were normalized to NC siRNA-transfected cells and reported as mean (±SEM) of three independent experiments.

  • 1/16

    Raltegravir potassium purchased from MedChemExpress. Usage Cited in: Life Sci. 2022 Nov 1:308:120948. [Abstract]

    Customer Validation
     Effects of dolutegravir, Raltegravir (0.1-10 μM) and bictegravir on adipogenic differentiation of SGBS human pre-adipocytes in culture. SGBS human pre-adipocytes were differentiated in culture in the presence of the indicated concentrations of drugs. Treatment was initiated on day 0 and continued throughout the differentiation process (10 days). Representative micrographs of adipocyte cell cultures differentiating in the presence of the indicated concentrations of drugs are shown.

  • 1/16

    Raltegravir potassium purchased from MedChemExpress. Usage Cited in: Life Sci. 2022 Nov 1:308:120948. [Abstract]

    Customer Validation
     Effects of dolutegravir (DTG), Raltegravir (RAL) (0.01-10 μM), and bictegravir (BIC) on the expression levels of inflammatory genes in differentiating SGBS human adipocytes. SGBS human pre-adipocytes were differentiated in culture in the presence of the indicated concentrations of drugs.

  • 1/16

    Raltegravir potassium purchased from MedChemExpress. Usage Cited in: Life Sci. 2022 Nov 1:308:120948. [Abstract]

    Customer Validation
     Effects of dolutegravir (DTG), Raltegravir (RAL) (0.1-10 μM), and bictegravir (BIC) on the release of leptin and adiponectin to the cell culture medium of differentiating SGBS human adipocytes. SGBS human pre-adipocytes were differentiated in culture in the presence of the indicated concentrations of drugs. Data corresponds to concentrations accumulating in the cell culture medium in the last 5 days of culture.

  • 1/16

    Raltegravir potassium purchased from MedChemExpress. Usage Cited in: J Mol Biol. 2022 Apr 15;434(7):167507. [Abstract]

    Customer Validation
     HIV-1 integrase strand transfer inhibition assays. Bar graphs represent strand transfer activity inhibition in assays carried out with heteropolymeric hybrids in the presence of β-thujaplicinol, SL-6h, WX-II-25, II-4, XQ9, YLC2-155, DW3, K04-9 and K04-81, at 1 µM (purple), 5 µM (green), 10 µM (red) and 25 µM (blue), and Raltegravir (5 min) at 1 µM.

  • 1/16

    Raltegravir potassium purchased from MedChemExpress. Usage Cited in: J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692. [Abstract]

    Customer Validation
     TDF/FTC/RAL combined medication induces mouse NPC apoptosis in vitro. Mouse NPCs are treated with either DMSO or TDF/FTC/RAL for 8 h. Cleaved Caspase-3 levels are determined by Western blotting.

  • 1/16

    Raltegravir potassium purchased from MedChemExpress. Usage Cited in: J Virol. 2017 Jan 18;91(3):e02152-16. [Abstract]

    Customer Validation
     Inhibitory effects of Raltegravir on pUL89-C activity analyzed by agarose gel assay. Linearized pUC18 in the absence (Lane 1) or presence (Lane 2) of pUL89-C. Lanes 3–10: A range of concentrations of Raltegravir with pUL89-C. Numbers above bands correspond to the fold change compared with the control.

  • Raltegravir potassium